Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 15/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 12/20 | 0.79 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.66 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12348444 | 0.98 | L3MBTL3 (0.81) | L3MBTL3L3MBTL1MBTD1TP53BP1KDM4E | |
| SCHEMBL23682775 | 0.89 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL15764103 | 0.86 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1HRH3ADRB1 | |
| SCHEMBL15764139 | 0.86 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1HRH3ADRB1 | |
| SCHEMBL2777044 | 0.86 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1HRH3ADRB1 | |
| SCHEMBL2777049 | 0.86 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1HRH3ADRB1 | |
| SCHEMBL12082369 | 0.84 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1KDM4E | |
| SCHEMBL13616253 | 0.84 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1KDM4E | |
| SCHEMBL82890 | 0.84 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1KDM4E | |
| SCHEMBL82007 | 0.84 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1HRH3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4169919-A1 | PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| US-11324720-B2 | Antiproliferative DNA polymerase inhibitor | NEW YORK MEDICAL COLLEGE (US) | 2022-05-10 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9345719-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2016-05-24 | — | — | US | disclosed |
| US-8957065-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
| US-8258129-B2 | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | L3MBTL3 3429/4885L3MBTL1 2596/4885MBTD1 754/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | L3MBTL3 3628/4885L3MBTL1 2790/4885MBTD1 799/4885 |
| US-11324720-B2 | Antiproliferative DNA polymerase inhibitor | POLB, POLI, PCNA | L3MBTL3 2327/4885L3MBTL1 2141/4885MBTD1 3314/4885 |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | CCNI, MKI67, CCNA1 | L3MBTL3 4313/4885L3MBTL1 3852/4885MBTD1 2394/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | L3MBTL3 3628/4885L3MBTL1 2790/4885MBTD1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.